This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gesu, G. P.
Right arrow Articles by Cavallero, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gesu, G. P.
Right arrow Articles by Cavallero, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 816-819, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.816-819.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Levofloxacin and Ciprofloxacin In Vitro Activities against 4,003 Clinical Bacterial Isolates Collected in 24 Italian Laboratories

Giovanni Pietro Gesu,1* Federico Marchetti,2 Laura Piccoli,3 and Annalisa Cavallero4

Medical Department,2 Medicine Research Center GlaxoSmithKline, Verona,3 Laboratorio Analisi, Cardiologico Monzino Hospital IRCCS,1 Clinical Microbiology Laboratory, S. Raffaele Hospital, Milan, Italy4

Received 10 December 2001/ Returned for modification 2 September 2002/ Accepted 1 November 2002

Levofloxacin showed comparable in vitro susceptibility to ciprofloxacin among Enterobacteriaceae, Pseudomonas aeruginosa, enterococci, and Staphylococcus aureus, while greater susceptibility was observed in Stenotrophomonas maltophilia and Staphylococcus epidermidis, mainly when oxacillin resistant. The susceptibility of Streptococcus pneumoniae to levofloxacin reached 99%.

* Corresponding author. Mailing address: Laboratorio di Analisi, Centro Cardiologico Monzino, Via Parea 4, Milan 20138, Italy. Phone: 39 0258002595. Fax: 39 0258002259. E-mail: ggesu{at}ccfm.it.

Antimicrobial Agents and Chemotherapy, February 2003, p. 816-819, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.816-819.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pea, F., Poz, D., Viale, P., Pavan, F., Furlanut, M. (2006). Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 58: 380-386 [Abstract] [Full Text]  
  • Kaye, K. S., Kanafani, Z. A., Dodds, A. E., Engemann, J. J., Weber, S. G., Carmeli, Y. (2006). Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa.. Antimicrob. Agents Chemother. 50: 2192-2196 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»